Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers

PLoS Pathogens

Volumn 2, Issue 1, 2006, Pages 0005-0013

  Warfield, Kelly L ^a   Swenson, Dana L ^a   Olinger, Gene G ^a   Nichols, Donald K ^a   Pratt, William D ^a   Blouch, Robert ^b   Stein, David A ^b   Aman, M Javad ^a   Iversen, Patrick L ^b   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b AVI BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTISENSE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; ANTIVIRUS AGENT; OLIGOMER; RNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS MESSENGER RNA; VIRUS PROTEIN; MORPHOLINE DERIVATIVE; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; VIRUS RNA; VP24 PROTEIN, EBOLA VIRUS; VP35 PROTEIN, VIRUS;

ARTICLE; EBOLA VIRUS; FATALITY; FILOVIRUS; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; PROTEIN TARGETING; RHESUS MONKEY; RODENT; VIRUS INFECTION; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; MACACA; MALE; MOUSE; NUCLEIC ACID PROBE; PHYSIOLOGY; PROTEIN SYNTHESIS; VIRUS HEMORRHAGIC FEVER; VIRUS REPLICATION;

EBOLA VIRUS; LAKE VICTORIA MARBURGVIRUS; MACACA MULATTA; MARBURGVIRUS; PRIMATES; RNA VIRUSES; RODENTIA;

ANIMALS; ANTISENSE ELEMENTS (GENETICS); EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; MACACA MULATTA; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; PROTEIN BIOSYNTHESIS; RNA, VIRAL; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 33644653708     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.0020001     Document Type: Article

References (40)

1. Geisbert TW, Hensley LE (2004) Ebola virus: New insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med 6: 1-24.
2. Burnett J, Henchal EA, Schmaljohn A, Bavari S (2005) The evolving field of biodefence: Therapeutic developments and diagnostics. Nat Rev Drug Disc 4: 281-297.
3. Geisbert T, Jahrling P (2003) Towards a Vaccine against Ebola Virus. Expert Rev Vaccines 2003: 777-789.
4. Outbreak(s) of Ebola haemorrhagic fever in the Republic of the Congo, January-April 2003. Wkly Epidemiol Rec 78: 285-289.
5. Outbreak(s) of Ebola hemorrhagic fever, Congo and Gabon, October 2001 to July 2002. . Can Commun Dis Rep 29: 129-133.
6. Outbreak of Marburg virus hemorrhagic fever-Angola, October 1, 2004-March 29, 2005. . MMWR Morb Mortal Wkly Rep 54: 308-309.
7. Bray M (2003) Defense against filoviruses used as biological weapons. Antiviral Res 57: 53-60.
8. Leffel EK, Reed DS (2004) Marburg and Ebola viruses as aerosol threats. Biosecur Bioterror 2: 186-191.
9. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, et al. (2002) Hemorrhagic fever viruses as biological weapons: Medical and public health management. JAMA 287: 2391-2405.
10. Alibek K, Handelman S (1999) Biohazard. New York: Random House. 319 p.
11. Feldmann H, Kiley MP (1999) Classification, structure, and replication of filoviruses. Curr Top Microbiol Immunol 235: 1-21.
12. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, et al. (2003) Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424: 681-684.
13. Jones SM, Feldmann H, Stroher U, Geisbert J, Fernando L, et al. (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11: 786-790.
14. Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, et al. (1999) Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis 179 (Suppl 1): S224-S234.
15. Warfield KL, Perkins JG, Swenson DL, Deal EM, Bosio CM, et al. (2004) Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med 200: 169-179.
16. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, et al. (2003) Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys. Lancet 362: 1953-1958.
17. Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 75: 280-284.
18. Stephenson ML, Zamecnik PC (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A 75: 285-288.
19. Kurreck J (2003) Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270: 1628-1644.
20. Iversen PL (2001) Phosphorodiamidate morpholino oligomers: Favorable properties for sequence-specific gene inactivation. Curr Opin Mol Ther 3: 235-238.
21. Iversen PL (2001) Phosphorodiamidate Morpholino Oligomers. In: Crooke ST, editor. Antisense Drug Technology. New York: Marcel Dekker. pp. 375-389.
22. Ghosh C, Stein D, Weller D, Iversen P (2000) Evaluation of antisense mechanisms of action. Methods Enzymol 313: 135-143.
23. Deas TS, Binduga-Gajewska I, Tilgner M, Ren P, Stein DA, et al. (2005) Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol 79: 4599-4609.
24. Stein DA, Skilling DE, Iversen PL, Smith AW (2001) Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev 11: 317-325.
25. Kinney RM, Huang CY, Rose BC, Kroeker AD, Dreher TW, et al. (2005) Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers. J Virol 79: 5116-5128.
26. Neuman BW, Stein DA, Kroeker AD, Churchill MJ, Kim AM, et al. (2005) Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. J Virol 79: 9665-9676.
27. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, et al. (2002) Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 128: 163-168.
28. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E (2001) Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 124: 453-460.
29. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, et al. (2000) Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355: 2210-2215.
30. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J (1998) A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178: 651-661.
31. Gibb TR, Bray M, Geisbert TW, Steele KE, Kell WM, et al. (2001) Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J Comp Pathol 125: 233-242.
32. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, et al. (2003) Pathogenesis of Ebola Hemorrhagic Fever in Cynomolgus Macaques: Evidence that Dendritic Cells Are Early and Sustained Targets of Infection. Am J Pathol 163: 2347-2370.
33. Hart MK (2003) Vaccine research efforts for filoviruses. Int J Parasitol 33: 583-595.
34. Arora V, Iversen PL (2001) Redirection of drug metabolism using antisense technology. Curr Opin Mol Ther 3: 249-257.
35. Summerton J, Weller D (1997) Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7: 187-195.
36. Neuman BW, Stein DA, Kroeker AD, Paulino AD, Moulton HM, et al. (2004) Antisense morpholino-oligomers directed against the 5′ end of the genome inhibit coronavirus proliferation and growth. J Virol 78: 5891-5899.
37. Moe JB, Lambert RD, Lupton HW (1981) Plaque assay for Ebola virus. J Clin Microbiol 13: 791-793.
38. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, et al. (1999) Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 179 Suppl 1: S203-S217.
39. Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, et al. (2003) Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A 100: 15889-15894.
40. + T Cell Responses Are Required for Protection against Lethal Ebola Virus Infection. J Immunol 175: 1184-1191.